Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery

NCT ID: NCT01053897

Last Updated: 2013-10-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 5 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-01-31
• Study Completion Date: 2011-10-31

Brief Summary

The primary objective of this study is to assess whether intradermal injections of GBT009 along full thickness incisions following surgery results in an improvement in scar appearance.

Conditions

Scar Formation

Keywords

GBT009; incisional scar; breast reconstruction

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

GBT009

Group Type: EXPERIMENTAL

GBT009

Intervention Type: BIOLOGICAL

Intradermal Injection following surgery

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: BIOLOGICAL

Intradermal Injection following surgery

Interventions

GBT009

Intradermal Injection following surgery

Intervention Type: BIOLOGICAL

Placebo

Intradermal Injection following surgery

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• be a female between 18 and 70 years of age, inclusive
• have a body mass index ≤ 32 kg/m2 and a body weight between 50 and 95 kg, inclusive
• be scheduled for a mastectomy with breast reconstruction surgery using an abdominal flap technique
• for women diagnosed with breast cancer, has standard of care treatment for breast cancer prior to surgery and will have standard of care treatment for breast cancer after surgery
• for subjects of childbearing potential, be surgically sterile or using an insertable, injectable, transdermal, or combination oral contraceptive approved by the FDA through completion of the study and have negative results on a serum pregnancy test done before administration of study medication (women who are postmenopausal [no menses for at least 2 years] are also eligible to participate)
• be able to understand the study procedures, agree to participate in the study program, and voluntarily provide written informed consent

Exclusion Criteria

• have clinically significant laboratory abnormalities at screening
• have, as determined by the investigator or the sponsor's medical monitor, a history or clinical manifestations of significant renal, hepatic, cardiovascular, metabolic, neurologic, psychiatric, coagulopathic disorder or other condition that would preclude participation in the study
• have received treatment for a severe, uncontrolled inflammatory disease or allergic condition within three months of screening
• have a life expectancy ≤ 2 years
• have a history of alcoholism or drug addiction or abuse within 5 years
• have evidence of a clinically significant abnormality upon evaluation of 12 lead ECG
• have evidence of any past or present clinically significant medical condition, including skin disease, that would impair wound healing
• have a history of keloid scar formation
• have existing scarring in the abdominal area of study that would interfere with the efficacy assessments
• have a history of (within the past 5 years) or an active malignancy, other than breast cancer
• have a breast cancer that has been staged at Stage IIIB, IIIC or IV
• have received a cytotoxic agent or have been treated with radiation within 90 days of screening and/or, in the opinion of the investigator, will likely require treatment in the 30 day period following the administration of study medication
• have received anticoagulation medication within 5 days of dosing with study medication
• have participated in any study involving an investigational product within 30 days before dosing with study medication
• have routinely used tobacco products within 6 months preceding the study period

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Garnet BioTherapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Garnet Study Manager

Role: STUDY_DIRECTOR

Garnet BioTherapeutics, Inc.

Locations

Garnet BioTherapeutics Investigational Site

Chicago, Illinois, United States

Garnet BioTherapeutics Investigational Site

Rochester, New York, United States

Countries

United States

Other Identifiers

GBT-09-001

Identifier Type: -

Identifier Source: org_study_id